At the Forefront of Developing
Novel Apoptosis Targeting Therapies

Ascentage Pharma (6855.HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 30 Phase I/II clinical trials in the US, Australia, and China.

The company’s core drug candidate HQP1351 was recently granted orphan drug and fast-track designations by the US Food and Drug Administration (FDA), and a New Drug Application for HQP1351 has been submitted in China. APG-2575, another key drug candidate of the company, was recently granted orphan drug designation by the FDA.


Founders have been dedicated to apoptosis targeting drug innovation
for one decade


Company Culture

Our Mission


To discovery and development of innovative first- and best-in-class therapies to address unmet medical needs globally.

Our Vision


To become a fully integrated globally-focused biotechnology company.

Our Values


Patients First




Founded in 2009,
Ascentage Pharma is headquartered in Suzhou, China

Founded in 2010, Ascentage Pharma is headquartered in Suzhou, China
Founded in 2010, Ascentage Pharma is headquartered in Suzhou, China